This makes the combination a particularly robust option for patients with conditions like NAFLD (Non-Alcoholic Fatty Liver Disease) or those seeking comprehensive metabolic support
Given GHRP-2s cortisol and prolactin activity, ask whether a reported effect could reflect those hormones rather than GH
Expected metabolic improvements Weight loss from semaglutide typically produces favorable changes in fasting glucose (decreases), HbA1c (decreases), triglycerides (decreases), LDL cholesterol (modest decrease), HDL cholesterol (modest increase), blood pressure (decreases with weight loss), and inflammatory markers like C-reactive protein (decreases)
Tirzepatide: yes (Zepbound for weight management, Mounjaro for T2D)
Prescribing trends mirrored this pattern: AOM semaglutide saw its largest monthly increase in July, stabilized from SeptemberNovember, then rose modestly in NovemberDecember and accelerated through February 2026